Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.
about
SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectivesSodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectivesCanagliflozin Treatment in Patients with Type 2 Diabetes MellitusCanagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 DiabetesComparative effectiveness of sodium-glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: protocol for a systematic review and network meta-analysisPractical combination therapy based on pathophysiology of type 2 diabetesImpact of sodium-glucose cotransporter 2 inhibitors on blood pressurePharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.Sodium-glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusionsOptimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trialsEffects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitusA post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysisCombination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin.An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patientsCanagliflozin-Induced Diabetic Ketoacidosis: Case Report and Review of the LiteratureMetabolic ketoacidosis with normal blood glucose: A rare complication of sodium-glucose cotransporter 2 inhibitors.Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An OverviewA review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy.Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetesLonger-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.Dapagliflozin combination therapy in type 2 diabetes mellitus.Population-based incidence of diabetic ketoacidosis in type 2 diabetes: medical claims data analysis in Japan.Acid-base and electrolyte disorders associated with the use of antidiabetic drugs.Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials.Ketoacidosis and SGLT2 inhibitor treatment: Analysis of FAERS data.Guidelines for managing diabetes in Ramadan.The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors.SGLT2-I in the Hospital Setting: Diabetic Ketoacidosis and Other Benefits and Concerns.Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia.Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.SGLT2 inhibitors in the management of type 2 diabetes.
P2860
Q26746901-4A4A3983-5A67-411E-80AA-8F1F3AC1E9E6Q26767263-7CD9E3F1-7A44-4B22-8170-47EBD9EAEF0FQ26777529-DFC3D6C4-B4FA-42C6-AC12-C2711947F2A4Q28072339-B23C0051-4322-40E8-9D30-2959268A9905Q28074573-922769C7-87EC-4464-9075-659169B5A16BQ28076530-073A53F6-1C69-4304-87C5-70FD6EE9FB3AQ28080114-4663899C-B6B0-45C0-B474-7802C95BDF5AQ30249371-552B809F-FD7A-446D-983B-74703727C281Q33625568-F4DF9611-921F-4697-9B75-5F33B79BD62CQ33820904-3E8F665C-A405-470D-8625-336E7A7EA5E7Q33835824-405B4ABD-CB73-43A1-ADF8-E6697BEEBED3Q33845734-129AC461-3E6D-43FE-A295-C3178CBC064AQ33871321-0D4182BF-7395-4A48-AAA7-7B563E394280Q36096350-6F212402-295A-484E-BF88-0F31F929F3FFQ36301818-40C03D66-B6BA-494D-9F29-42E9B5A949DFQ36303346-26BF9473-D294-43AC-B549-006E037F4EE5Q37114983-1F7E87CF-13CE-4E3E-A4A4-FE5C27C1F94FQ37231951-4481DB6C-D0E3-4220-968F-25ED97063A17Q37461536-BD5473F7-899D-4769-9D72-BF944843F50AQ37562484-703A59CF-7048-47F9-A69D-989F9D148F8EQ37588842-6F640B0B-213A-4448-B7C2-13B82E570BFFQ37697744-22D1528E-0D9F-49A1-A0FB-05125D4FC361Q37712199-35201F6A-6E34-4DAE-A4C3-8021305C01F9Q37722896-5D3CE1A9-1817-4204-B295-71F238063068Q37741752-EFD5BDCF-C93E-4E1E-B294-4062FB84533DQ38383470-EA9B355A-1B08-4FA3-A16F-B9CC73DAB6C6Q38619164-5E4D8CF2-170E-42AB-ADF0-BF5A7F5B6DB9Q38634051-B4332CAF-C7EE-4149-8CF4-335363299682Q38655885-7424EDC9-1642-4636-87CB-F8FAD881A00FQ38658251-83157B7E-0FBE-42C8-B785-17519FF47E57Q38663903-FF6FF87C-D8D6-436E-83DE-4700C8D5A5FDQ38665387-E150B42A-F790-490A-9F69-71207D1ABA39Q38708743-3269F29F-ED1D-4CDF-BF67-20A9C6C1A5E0Q38715153-F415853D-D2D3-49BF-8E32-114CA98E2EEAQ38734956-553E92D2-B5D0-438E-B2DA-1E0BC6CA2508Q38740284-02AA6218-AE0C-4041-8205-E6F68A6AF52AQ38778239-15EB1D7B-46F7-407D-B8D0-8F095B74C1A9Q38783203-1C18C083-1416-4990-AF68-BB8A28F8D87FQ38802437-D8CE17A6-5F8E-4D23-BABD-622693688BBFQ38857523-24A25AD9-6787-4389-B2C3-B6D7C3E5B297
P2860
Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Diabetic Ketoacidosis and Rela ...... e 2 Diabetes Clinical Program.
@ast
Diabetic Ketoacidosis and Rela ...... e 2 Diabetes Clinical Program.
@en
type
label
Diabetic Ketoacidosis and Rela ...... e 2 Diabetes Clinical Program.
@ast
Diabetic Ketoacidosis and Rela ...... e 2 Diabetes Clinical Program.
@en
prefLabel
Diabetic Ketoacidosis and Rela ...... e 2 Diabetes Clinical Program.
@ast
Diabetic Ketoacidosis and Rela ...... e 2 Diabetes Clinical Program.
@en
P2093
P2860
P356
P1433
P1476
Diabetic Ketoacidosis and Rela ...... e 2 Diabetes Clinical Program.
@en
P2093
Gary Meininger
Mehul Desai
Ngozi Erondu
P2860
P304
P356
10.2337/DC15-1251
P407
P577
2015-07-22T00:00:00Z